VLIYaNIE AKTOVEGINA NA FAGOTsITY KROVI PRI OKSIDATIVNOM STRESSE U PATsIENTOV S SERDEChNOY NEDOSTATOChNOST'Yu


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In vitro effects of the drug Actovegin (calf blood hemodialysate) on the formation of oxygen radicals by blood phagocytes in whole blood samples (50-100 μI) in patients with II-III NYHA functional class heart failure (HF) were evaluated. The changes of superoxide anion (O 2-) secretion were recorded using lucigenin-dependent chemiluminescence by «Biotox-7» luminometer. Bacterial tripeptid FMLP (Formyl-Methionyl-Leucyl-Phenylalanine) at a dose of 3 μМ was used as stimulant for phagocytes. Blood phagocytes in patients with HF were initially preactivated (primed), as evidenced by the spontaneous formation of oxygen radicals as a result of their interaction with the plastic wall of the cuvet, as well as the subsequent pronounced response to the FMLP. For the first time, in blood samples of patients with heart failure, it was found that Actovegin had dose-dependent effect on the spontaneous and FMLP-induced reduction of O 2- generation. Significant inhibitory effect was observed at doses above 1 mg/ml. Actovegin had completely suppressed phagocyte response to FMLP. In a cell-free system of generation of oxygen radicals, Actovegin had dose-dependent effect on their reduction. In combination of Actovegin with antioxidant Trolox, each of these drugs reduced or completely inhibited the effects of another drug. Based on the lack of additivity effect in action of Actovegin and Trolox, it was concluded that these drugs have the same mechanism of action. These data indicate that Actovegin may have anti-inflammatory effects and inhibit the oxidative stress in system hypoxia in different organs and tissues of patients with heart failure as a result of removing the oxygen radicals formed.

全文:

受限制的访问

参考

  1. Aukrust P., Damas J.K., Gullestad L. Immunomodulating therapy: new treatment modality in congestive heart failure. Congest Heart Fail., 2003; 9(2): 64-9.
  2. Remme W.J. Overview of the Relationship Between Ischemia and Congestive Heart Failure. Clin. Cardiol. 2000; 23(Suppl. IV): IV-4-IV-8.
  3. Aukrust P., Gullestad L., Ueland T., et al. Inflammation and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implication. Ann Med. 2005; 37(2): 74-85.
  4. Oikonomou E., Tousoulis D., Siiasos G., et al. The role of Inflammation in heart failure: New therapeutic approaches. Hellenic J. Cardiol. 2011; 52: 30-40.
  5. Santos C.X.C., Anikumar N., Zhang M., et al., Redox signaling in cardiac myocytes. Free Radic. Biol. Med. 2001; 50(7): 777-93.
  6. Choundhary G., Doudley S.C. Heart failure, oxidative stress, and ion channel modulation. Congestive Heart Failure. 2002; 8: 148-55.
  7. Jordan J.E., Zhi-Qing Zhao, Vinten-Jjhansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc.Res. 1999; 43: 860-78.
  8. Viswanathan G. Neutrophils and myocardial injury: Cause or Effect that is the Question! South. Med. J. 2008; 101(1): 19-28.
  9. Rashidi F., Rashidi A., Golmohamadi A. Does absolute neutrophilia predict early congestive heart failure after acute myocardial infarction? A cross-sectional study. South Med. 2008; 101(1): 19-23.
  10. Tranche I., Ghigliotti G., Mura M. Increased neutrophil lifespan in patients with congestive heart failure. Eur. J. Heart Failure. 2009; 11: 378-85.
  11. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 1999; 79(1): 215-62.
  12. Elmlinger M.W., Kriebel M., Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vivo. Neuromol Med. 2011; 13; 266-74.
  13. Buchmayer F., Pleiner J., Elmlinger M.W., et al. Actovegin: a biological drug for more than 5 decades.Wien Med. Wochenschr, 2011; 161(3-4); 80-8.
  14. Machicao F., Muresanu D.F., Hundsberger H., et al. Pleiotropic neuroprotective and metabolic effects of actovegin's mode of action. J.Neurol Sci. 2012; 322(1-2): 222-27.
  15. National guidelines and OSSN for the diagnosis and treatment of chronic heart failure (ththird revision) Heart failure. 2010; 11(1): 3-62. -(Russian) (Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность. 2010; 11(3): 3-62.
  16. Imada I., Sato E.F., Miyamoto M., et al. Analysis of Reactive Oxygen Species generated by neutrophils using a chemiluminescence probe L-012. Analyt. Biochem. 1999; 271: 53-8.
  17. Chen Y., Junger W.G. Measurement of oxidative burst in neutrophils. Methods Mol. Biol. 2012; 844: 115-24.
  18. Hamad I., Arda N., Pekmez M., et al. Intracellular scavenging activity of Trolox (6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid) in the fission yeast, Schizosaccharomyces pombe. J Nat. Sci. Biol. Med. 2010; 1(1): 16-21.
  19. Distelmaier F., Valsecchi F., Forkink M., et al. Trolox-sensitive reactive oxygen species regulate mitochondrial morphology, oxidative phosphorylation and cytosolic calcium handling in healthy cells. Antioxid Redox Signal. 2012; 17(12): 1657-69.
  20. Wozniak A., Betts W.H., Murphy G.A., Rokicinski M. Interleukin-8 primes human neutrophils for enhanced superoxide anion production. Immunology. 1993; 79: 608-15.
  21. Condliffe A.M., Hawkins Ph.T., Stephens L.R., et al. Priming of human neutrophil superoxide generation by tumour necrosis factor-α is signalled by enhanced phosphatidylinositol 3,4,5-trisphosphate but not inositol 1,4,5-trisphosphate accumulation. FEBS Letters, 1998; 439: 147-51.
  22. Swain St.D., Rohn Tr.T., Quinn M.T. Neutrophil Priming in Host Defense: Role of Oxidants as Priming Agents. Antioxidants & Redox Signaling. 2002; 4(1): 69-83.
  23. Lamb F.S., Hook J.S., Hilkin Br.M., et al. Endotoxin priming of neutrophils requires endocytosis and NADPH oxidase-dependent endosomal reactive oxygen species. J. Biol. Chem. 2012; 287: 12395-404.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##